Related Experiment Video
Updated: Jun 14, 2026
06:39
Through-the-Wall Blood Sampling Method to Minimize Sleep Disruption in Clinical Settings
Published on: June 13, 2025
Partial sleep restriction decreases insulin sensitivity in type 1 diabetes
Esther Donga1, Marieke van Dijk, J Gert van Dijk
1Department of Endocrinology and Metabolic Diseases, Leiden University Medical Centre, Leiden, the Netherlands. e.donga@lumc.nl
Diabetes Care
|April 2, 2010
Summary
Short sleep duration impairs insulin sensitivity in type 1 diabetes patients. A single night of restricted sleep significantly reduced glucose disposal, indicating peripheral insulin resistance. Sleep duration is a key factor for managing insulin sensitivity in this population.
Area of Science:
- Endocrinology
- Metabolic Health
- Sleep Medicine
Background:
- Sleep restriction is known to decrease insulin sensitivity and glucose tolerance in healthy individuals.
- The impact of sleep duration on insulin sensitivity in patients with type 1 diabetes remains less understood.
Purpose of the Study:
- To investigate whether sleep duration is a determinant of insulin sensitivity in patients with type 1 diabetes.
- To assess the effects of acute sleep restriction on glucose metabolism and insulin sensitivity in type 1 diabetes.
Main Methods:
- Seven patients with type 1 diabetes underwent polysomnography to assess sleep characteristics.
- Insulin sensitivity was measured using hyperinsulinemic euglycemic clamp studies with stable isotope tracers.
- Patients were studied after a normal sleep duration night and a restricted sleep (4 hours) night.
Main Results:
- Sleep restriction significantly reduced the glucose disposal rate during the clamp study (P=0.04).
- The rate of glucose infusion required to maintain euglycemia decreased by approximately 21% after sleep restriction (P=0.04).
- No significant changes were observed in basal glucose levels, NEFA levels, or endogenous glucose production.
Conclusions:
- A single night of partial sleep deprivation induces peripheral insulin resistance in patients with type 1 diabetes.
- Sleep duration is a significant determinant of insulin sensitivity in individuals with type 1 diabetes.
Related Concept Videos
01:22Diabetes Mellitus: Overview and Type I Subtype
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
01:19Type I Diabetes III: Clinical Manifestations
Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...
01:24Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:26Type II Diabetes I: Introduction
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...